Compare DNN & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNN | TMDX |
|---|---|---|
| Founded | 1954 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.2B |
| IPO Year | 1998 | 2019 |
| Metric | DNN | TMDX |
|---|---|---|
| Price | $3.23 | $68.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $6.50 | ★ $148.22 |
| AVG Volume (30 Days) | ★ 21.1M | 1.7M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | $403.36 | $24.25 |
| Revenue Next Year | N/A | $18.75 |
| P/E Ratio | ★ N/A | $343.30 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $1.51 | $60.11 |
| 52 Week High | $4.43 | $156.00 |
| Indicator | DNN | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 36.62 | 31.56 |
| Support Level | $2.56 | $60.11 |
| Resistance Level | $3.36 | $142.44 |
| Average True Range (ATR) | 0.19 | 4.65 |
| MACD | -0.06 | 0.48 |
| Stochastic Oscillator | 14.04 | 22.22 |
Denison Mines Corp is engaged in uranium mining-related activities, including the acquisition, exploration, development, and mining of uranium-bearing properties, as well as the processing, sale, and investment in uranium. The company's key properties include Wheeler River, Waterbury Lake, McClean Lake, Midwest, and others. It operates through two segments: the Mining segment and the Corporate and Other segment. The majority of the company's revenue is generated from the Mining segment, which includes activities related to exploration, evaluation, and development, mining, milling (including toll milling), and the sale of mineral concentrates.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.